Product Description
Mechanisms of Action: COX1 Inhibitor,Prostaglandin Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Transdermal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | China | Colombia | Dominican Republic | Egypt | India | Japan | Jordan | Korea | Lebanon | Malaysia | Mexico | Pakistan | Philippines | Saudi Arabia | Taiwan | Turkey | United Arab Emirates | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: LEAD CHEMICAL COMPANY, LIMITED
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Acute Pain
Phase 1: Myalgia|Osteoarthritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
JY-BE-LSLF-2024-042 | P1 |
Not yet recruiting |
Myalgia|Osteoarthritis |
2024-08-01 |
|
2020-003543-29 | P3 |
Active, not recruiting |
Acute Pain |
2022-05-07 |